Regular vs ad-lib albuterol for patients hospitalized with acute asthma

被引:5
作者
Chandra, A
Shim, C
Cohen, HW
Chung, V
Maggiore, D
Mani, K
Dhuper, S
机构
[1] Jocobi Med Ctr, Div Pulm Med, Bronx, NY 10461 USA
[2] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA
[3] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA
关键词
adrenergic beta-agonists; asthma; bronchodilator; drug therapy; randomized control trial;
D O I
10.1378/chest.128.3.1115
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Study objectives: Inhaled, short-acting beta-agonists and systemic corticosteroids form the mainstay, of therapy in acute asthma exacerbation. Asthma, however, is an inflammatory disease of the airways, and its underlying pathology is not impacted by short-acting beta-agonists. While the efficacy, of ad-lib beta-agonist administration in outpatient management of asthma symptoms is well established, little data exist to support this strategy, in patients with acute, severe asthma. We postulate that as long as patients hospitalized with severe asthma exacerbation receive systemic corticosteroids, regular, scheduled administration of short-acting beta-agonists is unnecessary. Similar therapeutic outcomes can be achieved with the ad-lib administration of the short-acting beta-agonists. Design: Prospective, randomized, double-blind, placebo-controlled trial. Setting: Pulmonary floor of a 600-bed municipal hospital. Patients or participants: Sixty-two patients hospitalized for acute asthma. Interventions: Patients were randomized to receive either albuterol. nebulizations (regular albuterol group) or saline solution nebulizations (ad-lib group) every 4 h with management of breakthrough symptoms with albuterol metered-dose inhaler or nebulizations for both groups. All patients received systemic corticosteroids. Peak expiratory flows, asthma symptoms, and need for rescue bronchodilator were followed up on each patient until discharge. Results: There was no significant difference in the length of hospitalization (median length, 48 h for ad-lib group vs 57.5 h for regular albuterol group, p = 0.82), rate of improvement in peak flow, or symptoms between the two groups. Ad-lib P-agonist use compared to regular albuterol scheduled use resulted in a significant reduction in the total number of albuterol treatments administered (median, 7 treatments vs 19 treatments, p = 0.001) during hospitalization. Conclusions: In the management of asthma exacerbation, ad-lib administration of albuterol is therapeutically, as effective as regular; scheduled administration. This method of drug administration also reduces the total dose of beta-agonists received by the hospitalized patient.
引用
收藏
页码:1115 / 1120
页数:6
相关论文
共 29 条
[1]   Anti-inflammatory effect of β2-agonists:: Inhibition of TNF-α release from human mast cells [J].
Bissonnette, EY ;
Befus, AD .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1997, 100 (06) :825-831
[2]   Asthma:: an inflammatory mediator soup [J].
Björnsdottir, US ;
Cypcar, DM .
ALLERGY, 1999, 54 :55-61
[3]   As-required versus regular nebulized salbutamol for the treatment of acute severe asthma [J].
Bradding, P ;
Rushby, I ;
Scullion, J ;
Morgan, MDL .
EUROPEAN RESPIRATORY JOURNAL, 1999, 13 (02) :290-294
[4]   Risk factors for asthma morbidity and mortality in a large metropolitan city [J].
Castro, M ;
Schechtman, KB ;
Halstead, J ;
Bloomberg, G .
JOURNAL OF ASTHMA, 2001, 38 (08) :625-635
[5]   CONTROLLED COMPARISON OF BRONCHODILATOR EFFECTS OF 3 BETA-ADRENERGIC STIMULANT DRUGS ADMINISTERED BY INHALATION TO PATIENTS WITH ASTHMA [J].
CHOOKANG, YF ;
SIMPSON, WT ;
GRANT, IWB .
BMJ-BRITISH MEDICAL JOURNAL, 1969, 2 (5652) :287-+
[6]   Socioeconomic factors and asthma hospitalization rates in New York City [J].
Claudio, L ;
Tulton, L ;
Doucette, J ;
Landrigan, PJ .
JOURNAL OF ASTHMA, 1999, 36 (04) :343-U27
[7]  
DUATZENBERG B, 2001, REV PNEUMOL CLIN, V57, P91
[8]  
FitzGerald JM, 1996, ANNU REV MED, V47, P161
[9]   Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled β-agonist treatment [J].
Hancox, RJ ;
Cowan, JO ;
Flannery, EM ;
Herbison, GP ;
McLachlan, CR ;
Taylor, DR .
RESPIRATORY MEDICINE, 2000, 94 (08) :767-771
[10]  
HORWITZ RJ, 1995, CLIN CHEST MED, V16, P583